The therapeutic potential of the use of gliclazide MV in combination with COVID-19 and type 2 diabetes mellitus-Reference-Cited by-同舟云学术

The therapeutic potential of the use of gliclazide MV in combination with COVID-19 and type 2 diabetes mellitus

Published:2024-05-07 Issue:1 Volume:5 Page:20-23
ISSN:2713-0185
Container-title:FOCUS. Endocrinology
language:
Short-container-title:jour

Author:

Belikina D. V.¹^ORCID,Nekrasova T. A.¹^ORCID,Strongin L. G.¹^ORCID,Durygina E. M.¹,Rodina M. Yu.¹

Affiliation:

1. Privolzhsky Research Medical University

Abstract

It is known that COVID-19 patients with concomitant type 2 diabetes mellitus and severe dyslexic disorders are characterized by a more severe course of combined pathology. In this regard, the choice of hypoglycemic therapy for effective management of glycemia is important. The review examines publications shedding light on the therapeutic potential of taking gliclazide MV in patients with a combination of mild COVID-19 and diabetes mellitus.

Publisher

Focus Endocrinology

Reference28 articles.

1. Deng S-Q, Peng H-J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J.Clin. Med. 2020;9(2):575. doi: 10.3390/jcm9020575

2. Dedov I. I., Mokrysheva N. G., Markova T. N. i dr. Kontrol' glikemii i vybor antigiperglikemicheskoi terapii u patsientov s sakharnym diabetom 2 tipa i COVID-19: konsensusnoe reshenie soveta ekspertov Rossiiskoi assotsiatsii endokrinologov. Sakharnyi diabet. 2022; 25(1):27–49. https://doi.org/10.14341/DM12873

3. Singh Tomar, P. P., Arkin I. T. SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine. Biochem Biophys Res Commun. – 2020. – Vol. 10. – Vol. 530 (1). – P. 10–14.

4. O’Brien R.C., Luo M., Balazs N., Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J DiabetCompl 2000; 14:201–206.

5. Scott N. A., Jennings P. E., Brown J., Belch J. J. Gliclazide: a general free radical scavenger. Eur J Pharmacol 1991; 208: 175–177.